A prospective study in the rational design of efficient antisense oligonucleotides for exon skipping in the DMD gene

Human Gene Therapy

Volumn 23, Issue 7, 2012, Pages 781-790

  Pramono, Zacharias Aloysius Dwi ^a   Wee, Keng Boon ^b   Wang, Jian Li ^c   Chen, Yi Jun ^d   Xiong, Qian Bin ^d   Lai, Poh San ^e   Yee, Woon Chee ^d  

^a NATIONAL SKIN CENTRE   (Singapore)

^b INSTITUTE OF HIGH PERFORMANCE COMPUTING   (Singapore)

^c NATIONAL NEUROSCIENCE INSTITUTE   (Singapore)

^d SINGAPORE GENERAL HOSPITAL   (Singapore)

^e NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE;

CONTROLLED STUDY; DUCHENNE MUSCULAR DYSTROPHY GENE; EXON; EXON SKIPPING; GENE; GENE TARGETING; HUMAN; HUMAN CELL; HUMAN TISSUE; PRACTICE GUIDELINE; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; REVIEW;

ALGORITHMS; ALTERNATIVE SPLICING; BASE SEQUENCE; CELLS, CULTURED; COMPUTER SIMULATION; DYSTROPHIN; EXONS; GENETIC THERAPY; HUMANS; MODELS, MOLECULAR; MUSCULAR DYSTROPHY, DUCHENNE; MYOBLASTS; NUCLEIC ACID CONFORMATION; OLIGONUCLEOTIDES, ANTISENSE; PROSPECTIVE STUDIES; PROTEIN ISOFORMS; RNA PRECURSORS;

EID: 84864351202     PISSN: 10430342     EISSN: 15577422     Source Type: Journal    
DOI: 10.1089/hum.2011.205     Document Type: Review

References (34)

1. Aartsma-Rus, A. (2010). Antisense-mediated modulation of splicing: therapeutic implications for Duchenne muscular dystrophy. RNA Biol. 7, 453-461.
2. Aartsma-Rus, A., De Winter, C.L., Janson, A.A., et al. (2005). Functional analysis of 114 exon-internal AONs for targeted DMD exon skipping: indication for steric hindrance of SR protein binding sites. Oligonucleotides 15, 284-297. (Pubitemid 43108225)
3. Aartsma-Rus, A., and Van Ommen, G.J. (2007). Antisensemediated exon skipping: a versatile tool with therapeutic and research applications. RNA 13, 1609-1624. (Pubitemid 47481669)
4. Aartsma-Rus, A., Fokkema, I., Verschuuren, J., et al. (2009a). Theoretic applicability of antisense-mediated exon skipping for duchenne muscular dystrophy mutations. Hum. Mutat. 30, 293-299.
5. Aartsma-Rus, A., Van Vliet, L., Hirschi, M., et al. (2009b). Guidelines for antisense oligonucleotide design and insight into splice-modulating mechanisms. Mol. Ther. 17, 548-553.
6. Aartsma-Rus, A., Houlleberghs, H., Van Deutekom, J.C., et al. (2010). Exonic sequences provide better targets for antisense oligonucleotides than splice site sequences in the modulation of Duchenne muscular dystrophy splicing. Oligonucleotides 20, 69-77.
7. Arechavala-Gomeza, V., Graham, I.R., Popplewell, L.J., et al. (2007). Comparative analysis of antisense oligonucleotide sequences for targeted skipping of exon 51 during dystrophin pre-mrna splicing in human muscle. Hum. Gene Ther. 18, 798-810. (Pubitemid 47502846)
8. Cartegni, L., Wang, J., Zhu, Z., et al. (2003). ESEfinder: a web resource to identify exonic splicing enhancers. Nucleic Acids Res. 31, 3568-3571. (Pubitemid 37442199)
9. Dominski, Z., and Kole, R. (1993). Restoration of correct splicing in thalassemic pre-mRNA by antisense oligonucleotides. Proc. Natl. Acad. Sci. U. S. A. 90, 8673-8677. (Pubitemid 23277732)
10. Fairbrother, W.G., Yeh, R.F., Sharp, P.A., and Burge, C.B. (2002). Predictive identification of exonic splicing enhancers in human genes. Science 297, 1007-1013. (Pubitemid 34856033)
11. Faulkner, J.A., Brooks, S.V., Dennis, R.G., and Lynch, G.S. (1997). The functional status of dystrophic muscles and functional recovery by skeletal muscles following myoblast transfer. Basic Appl. Myol. 7, 257-264. (Pubitemid 127154639)
12. Goemans, N.M., Tulinius, M., Van Den Akker, J.T., et al. (2011). Systemic administration of PRO051 in Duchenne's muscular dystrophy. N. Engl. J. Med. 364, 1513-1522.
13. Gorman, L., Mercatante, D.R., and Kole, R. (2000). Restoration of correct splicing of thalassemic beta-globin pre-mRNA by modified U1 snRNAs. J. Biol. Chem. 275, 35914-9.
14. Graveley, B.R., Hertel, K.J., and Maniatis, T. (1999). SR proteins are 'locators' of the RNA splicing machinery. Curr. Biol. 9, R6-7. (Pubitemid 29045780)
15. Harding, P.L., Fall, A.M., Honeyman, K., et al. (2007). The influence of antisense oligonucleotide length on dystrophin exon skipping. Mol. Ther. 15, 157-166. (Pubitemid 46043661)
16. Heemskerk, H.A., De Winter, C.L., De Kimpe, S.J., et al. (2009). In vivo comparison of 2¢-O-methyl phosphorothioate and morpholino antisense oligonucleotides for Duchenne muscular dystrophy exon skipping. J. Gene Med. 11, 257-266.
17. Kinali, M., Arechavala-Gomeza, V., Feng, L., et al. (2009). Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a singleblind, placebo-controlled, dose-escalation, proof-of-concept study. Lancet Neurol. 8, 918-928.
18. Lam, B.J., and Hertel, K.J. (2002). A general role for splicing enhancers in exon definition. RNA 8, 1233-1241.
19. Maniatis, T., and Reed, R. (2002). An extensive network of coupling among gene expression machines. Nature 416, 499-506. (Pubitemid 34288845)
20. McGlincy, N.J., and Smith, C.W. (2008). Alternative splicing resulting in nonsense-mediated mRNA decay: what is the meaning of nonsense? Trends Biochem. Sci. 33, 385-393.
21. Mercatante, D.R., Sazani, P., and Kole, R. (2001). Modification of alternative splicing by antisense oligonucleotides as a potential chemotherapy for cancer and other diseases. Curr Cancer Drug Targets 1, 211-230. (Pubitemid 33772978)
22. Mitrpant, C., Adams, A.M., Meloni, P.L., et al. (2009). Rational design of antisense oligomers to induce dystrophin exon skipping. Mol. Ther. 17, 1418-1426.
23. Neri, M., Torelli, S., Brown, S., et al. (2007). Dystrophin levels as low as 30% are sufficient to avoid muscular dystrophy in the human. Neuromuscul. Disord. 17, 913-918. (Pubitemid 350137731)
24. Popplewell, L.J., Trollet, C., Dickson, G., and Graham, I.R. (2009). Design of phosphorodiamidate morpholino oligomers (PMOs) for the induction of exon skipping of the human DMD gene. Mol. Ther. 17, 554-561.
25. Popplewell, L.J., Adkin, C., Arechavala-Gomeza, V., et al. (2010). Comparative analysis of antisense oligonucleotide sequences targeting exon 53 of the human DMD gene: implications for future clinical trials. Neuromuscul. Disord. 20, 102-110.
26. Popplewell, L.J., Graham, I.R., Malerba, A., and Dickson, G. (2011). Bioinformatic and functional optimization of antisense phosphorodiamidate morpholino oligomers (PMOs) for therapeutic modulation of RNA splicing in muscle. Methods Mol. Biol. 709, 153-178.
27. Sharp, P.S., Bye-a-Jee, H., and Wells, D.J. (2011). Physiological characterization of muscle strength with variable levels of dystrophin restoration in mdx mice following local antisense therapy. Mol. Ther. 19, 165-171.
28. Suwanmanee, T., Sierakowska, H., Fucharoen, S., and Kole, R. (2002). Repair of a splicing defect in erythroid cells from patients with beta-thalassemia/HbE disorder. Mol. Ther. 6, 718-726. (Pubitemid 36054305)
29. Tennyson, C.N., Klamut, H.J., and Worton, R.G. (1995). The human dystrophin gene requires 16 hours to be transcribed and is cotranscriptionally spliced. Nat. Genet. 9, 184-190.
30. van Deutekom, J.C., Janson, A.A., Ginjaar, I.B., et al. (2007). Local dystrophin restoration with antisense oligonucleotide pro051. N. Engl. J. Med. 357, 2677-2686.
31. Vetrini, F., Tammaro, R., Bondanza, S., et al. (2006). Aberrant splicing in the ocular albinism type 1 gene (OA1/GPR143) is corrected in vitro by morpholino antisense oligonucleotides. Hum. Mutat. 27, 420-426. (Pubitemid 43673328)
32. Wee, K.B., Pramono, Z.A., Wang, J.L., et al. (2008). Dynamics of co-transcriptional pre-mRNA folding influences the induction of dystrophin exon skipping by antisense oligonucleotides. PLoS One 3, e1844.
33. Wilton, S.D., Fall, A.M., Harding, P.L., et al. (2007). Antisense oligonucleotide-induced exon skipping across the human dystrophin gene transcript. Mol. Ther. 15, 1288-1296. (Pubitemid 46965325)
34. Zuker, M. (2003). Mfold web server for nucleic acid folding and hybridization prediction. Nucleic Acids Res. 31, 3406-3415. (Pubitemid 37442169)